Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coya Therapeutics (COYA) Shares Outstanding (Weighted Average) (2022 - 2025)

Coya Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $16.7 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 9.89% year-over-year to $16.7 million; the TTM value through Sep 2025 reached $16.7 million, up 9.89%, while the annual FY2024 figure was $15.2 million, 49.93% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $16.7 million at Coya Therapeutics, roughly flat from $16.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $16.7 million in Q3 2025 and bottomed at $2.6 million in Q1 2022.
  • The 4-year median for Shares Outstanding (Weighted Average) is $10.2 million (2023), against an average of $10.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 292.4% in 2023 before it grew 9.89% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $2.6 million in 2022, then skyrocketed by 292.4% to $10.2 million in 2023, then soared by 49.93% to $15.2 million in 2024, then rose by 9.76% to $16.7 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Shares Outstanding (Weighted Average) are $16.7 million (Q3 2025), $16.7 million (Q2 2025), and $16.7 million (Q1 2025).